These variable results suggest that IL-2 levels in CSF may not be a clear marker for monitoring the progression of MS, but our results highlight the potential importance of IL-2 as an indicator of disease activity and progression in newly diagnosed RRMS cases. The gene discussed is IL2; the disease is relapsing-remitting multiple sclerosis.